We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.50 | 6.00 | 6.48 | - | 121,343 | 12:03:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.74 | 13.09M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/3/2020 18:16 | 21 Mar '20 - 17:06 - 382 of 383 Edit 0 0 0 likya for you dave44 | hazl | |
22/3/2020 18:08 | 44.2% or 49m shares in public hands!22m were traded Thursday and Friday so if half were buys that reduces the available shares to 38m!Presumably a good number will want to keep them for the medium term so that means we are likely to get a really big upward squeeze on the SP! | dave444 | |
22/3/2020 18:06 | Markets don't close! | dave444 | |
22/3/2020 18:02 | Hazl, then you'd better get as many SNG as you can before it shuts! Haha Just to let you know the markets are run electronically, by computers so will not shut. This isn't xmas day, it's a pandemic! | likya123 | |
22/3/2020 17:59 | I think people will have to careful generally,in the stock market, at the moment. There had been even the request, of closing markets, at one point. Be careful out there folks! IMO | hazl | |
22/3/2020 17:57 | Sorry I hadn't read previous posts and got that from LSE. That was why I asked the question rather than stating as a fact. I see that had already been brought up here. | hazl | |
22/3/2020 17:51 | Thank you toffeeman it was the first I had heard of it. | hazl | |
22/3/2020 17:41 | Some people seriously need to take a chill pill...the past week this thread has been derailed by a lot of drivel and personal agendas which is burying useful and relevant posts. | adman50 | |
22/3/2020 17:36 | From the 18th March RNS Wow!! In black and white...we've been approached and are in discussions! This is very fast moving indeed! "Since the outbreak of COVID-19, Synairgen has been approached by, and is in discussion with, a number of other medical, scientific, and Governmental bodies (both in the UK, US and internationally) seeking to investigate novel therapeutics in this area" | likya123 | |
22/3/2020 15:52 | No it's not! AZN and SNG entered into a conditional licensing agreement which came to nothing. | toffeeman | |
22/3/2020 15:50 | Is it true that AZ wanted to take Synairgen for £230 million about 3 years ago.? I read on a different board. | hazl | |
22/3/2020 15:46 | So obviously what everybody is looking for is potential treatments which could either reduce the severity of the disease or, ideally, to cure it all together. “So a number of different sorts of approaches have been suggested.” University of Southampton researchers are trialling the inhaled drug. The trial will involve 100 patients at Southampton and up to 10 other NHS hospitals. Participants will receive the current Covid-19 care, while inhaling either a placebo or SNG001 - a special formulation of the naturally occurring antiviral protein interferon beta 1a (IFN-beta), for 14 days. The trial will be undertaken with Synairgen, a drug development company founded by University of Southampton professors. | hazl | |
22/3/2020 15:44 | 'Researchers in Southampton are conducting the trial and Nottingham University Hospitals have confirmed that they have joined and local patients can be included in it. ' link above thanks to warrenbe | hazl | |
22/3/2020 15:41 | There is a consistent message,whenever a share has gone up a lot,by the envious. That's all it is,usually. | hazl | |
22/3/2020 15:36 | Nobbygnome - Ammu is a troll. He was asking same question on NYCT board. Best to ignore him or ban him. He is very disruptive. The question he asked is very embarrassing for someone who is on a share discussion board. | sellsell | |
22/3/2020 15:33 | Why on earth is everybody talking of placing?! We ought to be sitting back smugly,delighted at the recent news! This went up over 50% for a reason on Friday and its the best hope we have to fight back on this wretched virus! Better than tests, better than advice, better than anything I've heard of so far! Wheres the info again! | hazl | |
22/3/2020 15:28 | >> ammu Someone else hovering on the brink as I presume you are deliberately asking leading questions. Go and look at the results if you want to know the answer. | nobbygnome | |
22/3/2020 15:25 | How much money did they made last year ? | ammu12 | |
22/3/2020 15:19 | Well if it was tomorrow morning I would guess 48-50p after the strong rise late on Friday. It will not be at a big discount that’s for sure. And it may never happen if they sign some sort of marketing deal. | nobbygnome | |
22/3/2020 15:18 | Be Draconian Nobby! | toffeeman | |
22/3/2020 15:16 | What price would they do a placing at ? | ammu12 | |
22/3/2020 15:00 | Jeez! No they weren’t going to take them over; it was just a licensing deal with certain financial terms.... | nobbygnome | |
22/3/2020 14:57 | Ok Nobby, so there was a deal to takover Synairgen by Astra Zeneca for $232 million 3 years ago if certain milestones were met over the course of a number of years...is that still the case? And what price if covid-19 trials are a success? | likya123 | |
22/3/2020 14:55 | Someone on here today cited the previous AZN deal and the INEXAS study that was terminated by AZN with the rights to AZD9412 returned to Synairgen. The reason for the termination was that the drugs affect on severe exacerbations could not be determined. In particular they mention cold infections not affecting trial patients asthma. I am assuming that AZD9412 is the same as SNG001 but does anyone know if the company followed up on this and whether they undertook any other study to evaluate this exacerbation. Just curious. | davew28 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions